NASH kNOWledge Launches Spanish Language Website to Address Community Need for Those at Risk for Nonalcoholic Liver Disease
June 28, 2022 09:00 ET
|
NASH EDUCATION
PITTSBURGH, June 28, 2022 (GLOBE NEWSWIRE) -- NASH kNOWledge today announced the launch of HigadoGraso.org, a new Spanish language website that provides information for those at-risk for...
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
June 25, 2022 09:00 ET
|
Madrigal Pharmaceuticals, Inc.
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan...
International NASH Day Highlights a Common – But Unfamiliar – Liver Disease
June 08, 2022 18:04 ET
|
Global Liver Institute
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this...
Madrigal Pharmaceuticals Supports International NASH Day on June 9
June 06, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
June 02, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
May 17, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
May 04, 2022 08:37 ET
|
The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
April 28, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
March 09, 2022 16:30 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
February 24, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...